AU2014246728B2 - Anti-inflammatory synergistic combinations comprising omega-3 fatty acid and tomato lycopene - Google Patents

Anti-inflammatory synergistic combinations comprising omega-3 fatty acid and tomato lycopene Download PDF

Info

Publication number
AU2014246728B2
AU2014246728B2 AU2014246728A AU2014246728A AU2014246728B2 AU 2014246728 B2 AU2014246728 B2 AU 2014246728B2 AU 2014246728 A AU2014246728 A AU 2014246728A AU 2014246728 A AU2014246728 A AU 2014246728A AU 2014246728 B2 AU2014246728 B2 AU 2014246728B2
Authority
AU
Australia
Prior art keywords
another embodiment
omega
composition
present
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014246728A
Other languages
English (en)
Other versions
AU2014246728A1 (en
Inventor
Nurit HADAD
Rachel Levy
Masha SAPOJNIK
Tanya Sedlov
Morris Zelkha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lycored Ltd
Original Assignee
Lycored Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lycored Ltd filed Critical Lycored Ltd
Publication of AU2014246728A1 publication Critical patent/AU2014246728A1/en
Application granted granted Critical
Publication of AU2014246728B2 publication Critical patent/AU2014246728B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/035—Halogenated hydrocarbons having aliphatic unsaturation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2014246728A 2013-04-04 2014-04-03 Anti-inflammatory synergistic combinations comprising omega-3 fatty acid and tomato lycopene Ceased AU2014246728B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361808246P 2013-04-04 2013-04-04
US61/808,246 2013-04-04
PCT/IL2014/050329 WO2014162313A1 (en) 2013-04-04 2014-04-03 Anti-inflammatory synergistic combinations comprising omega-3 fatty acid and tomato lycopene

Publications (2)

Publication Number Publication Date
AU2014246728A1 AU2014246728A1 (en) 2015-10-29
AU2014246728B2 true AU2014246728B2 (en) 2019-01-31

Family

ID=51657661

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014246728A Ceased AU2014246728B2 (en) 2013-04-04 2014-04-03 Anti-inflammatory synergistic combinations comprising omega-3 fatty acid and tomato lycopene

Country Status (7)

Country Link
US (2) US9901562B2 (enExample)
EP (1) EP2981256B1 (enExample)
JP (2) JP2016519101A (enExample)
CN (1) CN105407885B (enExample)
AU (1) AU2014246728B2 (enExample)
ES (1) ES2932248T3 (enExample)
WO (1) WO2014162313A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9901562B2 (en) * 2013-04-04 2018-02-27 Lycored Ltd. Anti-inflammatory omega-3 synergistic combinations
CN108354919A (zh) * 2017-12-29 2018-08-03 广东海洋大学 一种用于提高抗氧化功能的不饱和脂肪酸组合物及其应用
CN111053248A (zh) * 2018-10-16 2020-04-24 东莞市维康医疗投资有限公司 一种地龙蛋白口服液及其制备方法
CA3153891A1 (en) 2019-10-09 2021-04-15 Gregory CUMBERFORD Compositions with purified bombyx mori cocoon silk peptide fiber and refined buglossoides arvensis seed oil, and related methods
US11707497B2 (en) 2019-10-09 2023-07-25 Brain Health Holding Llc Methods and compositions with purified Bombyx mori cocoon silk peptide fiber and refined Buglossoides arvensis seed oil providing anti-inflammatory effects and neuroprotection for disease states
EP4041207B1 (en) * 2019-10-10 2026-02-25 Lycored Ltd. Compositions and methods for inhibiting collagen loss
US12582692B2 (en) 2024-01-03 2026-03-24 Hazel's Holistic, Llc Methods and kits for reducing microplastics levels and/or reducing or minimizing microplastics accumulation rates in subjects

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011057183A1 (en) * 2009-11-06 2011-05-12 Alcon Research, Ltd. Nutritional supplements for relief of dry eye

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837311A (en) 1993-12-13 1998-11-17 Makhteshim Chemical Works Ltd. Industrial processing of tomatoes and product thereof
ATE264063T1 (de) 1998-02-13 2004-04-15 Nestle Sa Garnierte toast
WO2001051088A1 (en) * 2000-01-07 2001-07-19 Anthony Cincotta Composition for reducing plasma triglycerides, platelet aggregation, and oxidative capacity
AU2003205737A1 (en) 2002-02-15 2003-09-04 Humboldt Universitaet Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies
JP2009537467A (ja) 2006-05-15 2009-10-29 ディーエスエム アイピー アセッツ ビー．ブイ． 前立腺癌に対する新規活性物
KR20090109793A (ko) * 2008-04-16 2009-10-21 홉킨스바이오연구센터(주) 크랜베리 추출물 또는 복분자 추출물을 함유하는건강기능성식품 조성물
JP5778584B2 (ja) 2009-01-19 2015-09-16 ライコード・リミテツド カロテノイドとポリフェノールとの相乗的組み合わせ
US20110008901A1 (en) 2009-07-07 2011-01-13 Kiernan Urban A Apolipoprotein ciii in pre- and type 2 diabetes
EP2976070B1 (en) * 2013-03-19 2021-05-12 Lycored Ltd. Anti-inflammatory synergistic combinations of astaxanthin with lycopene and carnosic acid
US9901562B2 (en) * 2013-04-04 2018-02-27 Lycored Ltd. Anti-inflammatory omega-3 synergistic combinations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011057183A1 (en) * 2009-11-06 2011-05-12 Alcon Research, Ltd. Nutritional supplements for relief of dry eye

Also Published As

Publication number Publication date
EP2981256B1 (en) 2022-08-24
AU2014246728A1 (en) 2015-10-29
EP2981256A4 (en) 2016-11-23
US20160303063A1 (en) 2016-10-20
US20180153843A1 (en) 2018-06-07
JP2016519101A (ja) 2016-06-30
WO2014162313A1 (en) 2014-10-09
EP2981256A1 (en) 2016-02-10
US9901562B2 (en) 2018-02-27
CN105407885B (zh) 2019-04-30
US10154980B2 (en) 2018-12-18
JP6803898B2 (ja) 2020-12-23
ES2932248T3 (es) 2023-01-17
CN105407885A (zh) 2016-03-16
JP2019052168A (ja) 2019-04-04

Similar Documents

Publication Publication Date Title
US10245239B2 (en) Astaxanthin anti-inflammatory synergistic combinations
US10154980B2 (en) Anti-inflammatory omega-3 synergistic combinations
CN102802636B (zh) 藏花素水解产物
CN102481269A (zh) 利用表观代谢转变剂(辅酶q10)治疗疾病的方法
JP5808772B2 (ja) 肝細胞内のミトコンドリアの活性化方法
JP5843169B2 (ja) フルクトース吸収阻害剤
WO2020021543A1 (en) Cannabidiol and curcumin for treating inflammatory diseases
JP5711616B2 (ja) Ｉｌ−１７産生抑制剤
US20230010958A1 (en) Cannabinoid and lycopene anti-inflammatory synergistic combinations
JP2016138082A (ja) 抗疲労薬および抗疲労食品
JP2003095931A (ja) 潰瘍性大腸炎および／又はクローン病治療剤
JP2014221734A (ja) ジンゲロール類を有効成分として含有する肝細胞活性化剤、並びに該肝細胞活性化剤を含有する固形製剤、液状製剤及び機能性食品

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired